Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Rifampicin on Selatogrel PK in Healthy Subjects
NCT03814200Phase 1Completed
- Sponsor
- Viatris
- Start
- Jan 2019
- Primary completion
- Feb 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of selatogrel in acute myocardial infarction (AMI) (2 arms), sponsored by Viatris. Primary endpoints: Area under the plasma concentration-time curve from time zero to time t up to 36 hours, Area under the plasma concentration-time curve from zero to infinity up to 36 hours and 3 more. Started Jan 2019; status: completed.
02
Drugs
selatogrel
03
Conditions
acute myocardial infarction (AMI)
Beyond the preview
Go deeper on NCT03814200.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03814200.